Developer docs
API playgroundTry for free, no card

Search company profiles

Re:Cognition Health

Full company profile

uuid000a2ev

Namestring
Re:Cognition Health
Legal namestring
Re:Cognition Health Limited
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Re:Cognition Health is a specialist cognitive healthcare provider operating 6 UK clinics (London/Harley Street, Birmingham, Bristol, Guildford, Plymouth, Winchester) and 4 US clinics (Fairfax, Chicago, Houston, Fort Worth), with a headcount of 74 employees. The company runs three integrated lines of business: (1) Phase II/III clinical trial services for global pharma and biotech sponsors across Alzheimer's, Mild Cognitive Impairment, Parkinson's, Huntington's, migraine, ADHD, autism and MS, generating fees per patient enrolled and randomized; (2) private-pay cognitive healthcare services including the integrated CognitionCheck assessment (combining AI-powered cognitive testing, MRI brain imaging, p-Tau217 blood biomarker analysis, and specialist physician consultation for adults aged 50+), administration of FDA-approved amyloid-targeting therapies Leqembi (lecanemab) and Kisunla (donanemab), ADHD and autism assessments, neurology, psychiatry and mental health services, with Medicare reimbursement accepted at US clinics; (3) medico-legal expert witness services in neurology, neuropsychiatry, neuroradiology and neuropsychology for personal injury and clinical negligence law firms, supported by 3T MRI and DTI imaging.

Revenue is generated primarily via per-patient professional services fees from pharmaceutical sponsors, self-pay private patients in the UK, Medicare-covered Alzheimer's infusions in the US, and per-report medico-legal fees from law firms. Go-to-market is hybrid: enterprise business development targeted at pharma/biotech sponsors (including through the PPD Select Partnership Programme with Thermo Fisher Scientific and Global Alzheimer's Platform Foundation membership), direct-to-consumer self-pay with NHS and private medical professional referrals, and sales-led outreach to personal injury solicitors. The company was founded in 2011, expanded to the US in 2018, and is led by co-founder and CEO Dr. Emer MacSweeney. It was the first organization globally to achieve GCSA clinical site certification from IAOCR in both the US and Europe, and is one of the largest providers of amyloid-targeting therapies in Europe.

Short descriptiontext

Re:Cognition Health operates 10 cognitive healthcare clinics across the UK and US, delivering Phase II/III clinical trials for global pharmaceutical sponsors, private-pay cognitive assessments and disease-modifying Alzheimer's treatments (Leqembi, Kisunla), and medico-legal expert witness services in neurology and brain injury.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cognitive healthcare services, clinical trial site network, Alzheimer's disease treatment, medico-legal expert witness, neurological assessment services
Industry4 codes
PRIMARYHLAKAIAH
Cognitive & Behavioral Neurology (Dementia/Memory Disorders)
SECONDARYHLADALAF
Dementia/Alzheimer’s Care Management & Behavioral Support
Healthcare & Life Sciences/Elder Care & Long-Term Care/Senior Care Coordination & Case Management (Geriatric Care Management)
SECONDARYHLADACAE
Behavioral Health–Integrated Dementia Care Communities (Neuropsychiatric/BPSD Programs)
Healthcare & Life Sciences/Elder Care & Long-Term Care/Memory Care (Dementia/Alzheimer’s) Communities
SECONDARYHSABAEAC
Alzheimer’s Specialized Care (Mid/Late-Stage)
Home & Personal Services/Elder Care & In-Home Care Services/Dementia & Alzheimer’s In-Home Care
NAICS code3 codes
  • Offices of Physicians, Mental Health Specialists621112
  • Offices of Mental Health Practitioners (except Physicians)621330
  • Services for the Elderly and Persons with Disabilities62412
SIC code2 codes
  • Services-Offices & Clinics Of Doctors Of Medicine8011
  • Services-Health Services8000
Product category
Neurology and Cognitive Healthcare Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Clinical Trial Services for Pharma & Biotech Sponsors
TypeProfessional Services
Description

Re:Cognition Health earns fees from pharmaceutical and biotech companies (Eli Lilly, AbbVie, ANAVEX, CervoMed, MSD, Sage Therapeutics, Biohaven, Amneal, AC Immune) for conducting Phase II–III clinical trials at their UK and US sites. Revenue is earned per patient enrolled, screened, and randomized, with study durations ranging from 6 weeks to 3 years. The company negotiates centralized contracts and budgets for multi-site UK/US trials.

recognitionhealth.com
2Private Pay Healthcare Services
TypeSubscription Recurring
Description

Revenue from self-pay patients accessing private cognitive health assessments (CognitionCheck), Alzheimer's disease-modifying treatments (Leqembi, Kisunla), ADHD and autism assessments, mental health services, neurology clinics, and therapeutic apheresis. Services are available to UK and international patients at the company's six UK clinic locations. Medicare coverage is accepted for FDA-approved Alzheimer's treatments at US clinics.

recognitionhealth.com
3Medico-Legal Expert Witness Services
TypeProfessional Services
Description

Revenue from law firms and barrister chambers for expert witness reports, medical assessments, 3T MRI scans, and court testimony in personal injury and clinical negligence cases involving brain injury, neurological conditions, and cognitive impairment. The company works with leading personal injury law firms on high-value catastrophic injury cases.

recognitionhealth.com
4Medicare Reimbursement (US Clinics)
TypeSubscription Recurring
Description

US clinics receive Medicare reimbursement for FDA-approved amyloid-targeting Alzheimer's medications (Leqembi and Kisunla) for early-stage Alzheimer's patients, providing a recurring revenue stream from the federal health insurance program at the company's four US clinic locations.

prnewswire.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels8 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details3 tiers
1Clinical trial participation — free to volunteers with expenses reimbursed
ModelOtherBilling cadencePay-as-you-go
Notes

Participants in clinical trials receive outstanding medical care including comprehensive health screens, MRI scans, PET scans, and specialist monitoring at no cost. Expenses are reimbursed. This enables access to new-generation drugs 4–5 years before market availability.

recognitionhealth.com
2Private cognitive health services — fee-based, quote on inquiry
ModelSubscriptionBilling cadencePay-as-you-go
Notes

CognitionCheck assessment (AI cognitive testing + MRI + p-Tau217 blood biomarker + physician consultation) and other private services are available as paid private-care services. Medicare coverage is available for FDA-approved Alzheimer's medications (Leqembi, Kisunla) at US clinics. NHS patients are referred through the Join Dementia Research registry or standard pathways.

recognitionhealth.com
3Medico-legal expert witness services — fee-based per report/assessment
ModelOtherBilling cadencePay-as-you-go
Notes

Expert witness reports, 3T MRI scans, and medico-legal assessments are billed to law firms and insurance companies on a per-service basis for personal injury and clinical negligence cases.

recognitionhealth.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

Re:Cognition Health operates a network of private cognitive healthcare clinics delivering AI-integrated diagnosis, disease-modifying Alzheimer's treatments (Leqembi and Kisunla), Phase II–III clinical trial site services for pharmaceutical and biotech sponsors, and medico-legal expert witness reports for personal injury and clinical negligence law firms. Its CognitionCheck assessment combines AI cognitive testing, MRI imaging, p-Tau217 blood biomarker analysis, and specialist physician consultation in a single pathway for adults aged 50 and over.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Kisunla (donanemab) slowed cognitive decline by 35% in total study population over 18 months, up to 60% in MCI participants, and reduced loss of daily function by 40%. One-third of patients achieved amyloid clearance by 6 months.
+5 more records
Product overview1 text field

Re:Cognition Health is a healthcare company offering a comprehensive portfolio of cognitive healthcare services centered around brain and mind health. The core offerings include CognitionCheck (AI-powered comprehensive cognitive assessment), Alzheimer's treatments (Leqembi and Kisunla), clinical trials for multiple neurological conditions, and private clinics. Additional services span ADHD and autism assessments, mental health services, neurology clinics, medico-legal expert witness services, and advanced imaging technologies including DTI. The company operates across multiple UK locations and four U.S. clinics, combining clinical care with research to advance treatments for Alzheimer's disease and other cognitive conditions.

Product and service5 records
1CognitionCheck
CategoryDiagnostic cognitive assessment
Description

A comprehensive cognitive health assessment for adults aged 50 and over combining AI-powered cognitive testing, MRI brain imaging, p-Tau217 blood biomarker analysis, and specialist physician consultation within a single integrated clinical pathway to detect early signs of Alzheimer's disease and cognitive decline.

2Alzheimer's Disease-Modifying Treatments (Leqembi and Kisunla)
CategoryDisease-modifying neurological therapy
Description

Private administration of monoclonal antibody therapies (Leqembi/lecanemab and Kisunla/donanemab) that target and clear amyloid-beta plaques in the brain to slow cognitive decline in early-stage Alzheimer's disease, with Medicare coverage for FDA-approved medications at US clinics.

3Clinical Trials (Phase II–III Site Services)
CategoryClinical research services
Description

Phase II–III clinical trial site services for pharmaceutical and biotech sponsors across Alzheimer's, Mild Cognitive Impairment, Parkinson's, ADHD, Migraine, Autism, and Multiple Sclerosis, including rapid study start-up, centralized UK/US contracting, and budget negotiation.

4Medico-Legal Expert Witness Services
CategoryMedico-legal services
Description

Expert witness reports and medical assessments in neurology, neuropsychiatry, neuroradiology, and neuropsychology for personal injury and clinical negligence cases involving brain injury, supported by 3T MRI and DTI imaging, with capacity assessments and court testimony.

5Private Cognitive Healthcare Clinics
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Cera
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-20
Description

Re:Cognition Health and Cera partnered in February 2026 to improve access to Alzheimer's Disease and neurodegenerative clinical trials by linking home care with specialist research centres. The collaboration aims to facilitate early referral, assessment, and trial participation for patients who are currently difficult to reach through traditional clinic-based methods. Home healthcare visits enable screening and monitoring that would otherwise require clinic visits, expanding the reach of clinical trials to housebound or mobility-limited patients.

digitalhealth.net
2Re:Cognition Health Brain and Mind Foundation
Strategic tierSupportingTypeOthersAnnounced on2025-12-01
Description

The Brain and Mind Foundation was launched by Re:Cognition Health in December 2025 to drive meaningful change, fund hope, and improve lives for those affected by neurological conditions. The Foundation harnesses the company's trans-Atlantic clinical expertise to fund breakthrough research, advance earlier diagnosis, and champion adoption of new biomarkers. It operates as a fundraising and research funding vehicle engaging donors, partners, and the wider community.

recognitionhealth.com
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2025-06-01
Description

Re:Cognition Health partnered with Scan.com to provide MRI imaging access to patients nationwide through a network of more than 300 imaging centres across the UK. This partnership makes CognitionCheck assessments geographically accessible to patients regardless of their proximity to company clinic locations, extending the reach of the company's diagnostic services across the entire UK.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-01
Description

Re:Cognition Health UK and US site networks are preferred sites within the PPD Select Partnership Programme of Thermo Fisher Scientific's PPD clinical research business, a global leader in clinical research. The relationship provides preferential access to clinical trial opportunities and strategic site collaborations across the company's 10 existing sites. This is described as an exciting relationship bringing significant opportunities for the company's clinical trial operations.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-06-01
Description

Re:Cognition Health is the only non-US/Canadian member of the Global Alzheimer's Platform Foundation, a patient-centric nonprofit dedicated to speeding the delivery of innovative Alzheimer's therapies by reducing the time and cost of clinical trials. This membership provides access to a global network of research sites and pharma partnerships, and positions the company as a preferred global partner for Alzheimer's clinical research.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-06-01
Description

The first US clinic (Fairfax, Virginia) operates in partnership with Inova Memory Center at Inova Fairfax Hospital. Dr. James Bicksel, Neurologist and Medical Director of Inova Memory Center, serves as Principal Investigator at the US site. The Inova Memory Center is a leading memory programme in the Washington D.C. area, adding clinical credibility and referral pathways to the company's US operations.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based provider of digital cognitive assessment technologies used in clinical trials and healthcare. Highly comparable because both companies deliver cognitive testing to pharma trial sponsors and run proprietary assessment platforms (CognitionCheck vs CANTAB).

TypeDirect peer
Description

UK-based clinical trial site network operating dedicated early and late-phase research clinics. Directly comparable to Re:Cognition Health's UK trial operations — both are private UK site networks running multi-therapeutic Phase II–III studies for global pharma sponsors.

TypeEmerging player
Description

Clinical-stage neuroscience company using biomarkers to develop precision psychiatry therapeutics and running trials in depression and ADHD. Comparable emerging overlap with Re:Cognition Health's adult ADHD assessment and psychiatry services for CNS drug development.

TypeOthers
Description

Provider of tau PET imaging ligands used in Alzheimer's disease clinical research. Comparable as an adjacent enabling partner in the same Alzheimer's biomarker ecosystem that Re:Cognition Health's CognitionCheck and clinical trial business operates within.

TypeBroad incumbent
Description

Global clinical trial technology and imaging company (formed via merger of Bioclinica and ERT) supporting CNS trials with imaging, eCOA, and biomarker solutions. Comparable as a broad incumbent serving the same pharma sponsors on neurodegenerative trials that Re:Cognition Health runs as a site.

6IXICO
TypeBroad incumbent
Description

UK-listed neuroimaging analytics company providing imaging biomarkers and AI tools for neurodegenerative clinical trials. Comparable to Re:Cognition Health's DTI/3T MRI and CognitionCheck imaging components, but operates as a technology vendor rather than a clinic operator.

TypeDirect peer
Description

Australia/US-based provider of computerized cognitive testing for clinical trials, healthcare, and academic research. Comparable to Re:Cognition Health as both monetize cognitive assessment in pharma-sponsored trials and neurodegenerative drug development.

TypeRegional player
Description

US-based memory disorders clinical and research program operated within Inova Fairfax Hospital. Comparable to Re:Cognition Health's Fairfax US site as both deliver specialist Alzheimer's and memory-disorder diagnosis, treatment, and clinical trial participation in the Washington DC metropolitan area.

TypeDirect peer
Description

UK clinical research organization specializing in early-phase clinical trials, including CNS studies. Comparable because it operates UK-based clinical trial infrastructure serving global pharma — similar customer base and regulatory complexity to Re:Cognition Health's trial services.

TypeDirect peer
Description

UK-headquartered mental health clinical-stage company running psychedelic therapy clinical trials for treatment-resistant depression. Comparable because both operate UK-based specialist clinical research operations for CNS indications targeting a similar regulatory and patient-recruitment environment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Re:Cognition Health

Neurology and Cognitive Healthcare Servicesrecognitionhealth.com

Re:Cognition Health operates 10 cognitive healthcare clinics across the UK and US, delivering Phase II/III clinical trials for global pharmaceutical sponsors, private-pay cognitive assessments and disease-modifying Alzheimer's treatments (Leqembi, Kisunla), and medico-legal expert witness services in neurology and brain injury.

What Re:Cognition Health does

Re:Cognition Health is a specialist cognitive healthcare provider operating 6 UK clinics (London/Harley Street, Birmingham, Bristol, Guildford, Plymouth, Winchester) and 4 US clinics (Fairfax, Chicago, Houston, Fort Worth), with a headcount of 74 employees. The company runs three integrated lines of business: (1) Phase II/III clinical trial services for global pharma and biotech sponsors across Alzheimer's, Mild Cognitive Impairment, Parkinson's, Huntington's, migraine, ADHD, autism and MS, generating fees per patient enrolled and randomized; (2) private-pay cognitive healthcare services including the integrated CognitionCheck assessment (combining AI-powered cognitive testing, MRI brain imaging, p-Tau217 blood biomarker analysis, and specialist physician consultation for adults aged 50+), administration of FDA-approved amyloid-targeting therapies Leqembi (lecanemab) and Kisunla (donanemab), ADHD and autism assessments, neurology, psychiatry and mental health services, with Medicare reimbursement accepted at US clinics; (3) medico-legal expert witness services in neurology, neuropsychiatry, neuroradiology and neuropsychology for personal injury and clinical negligence law firms, supported by 3T MRI and DTI imaging.

Revenue is generated primarily via per-patient professional services fees from pharmaceutical sponsors, self-pay private patients in the UK, Medicare-covered Alzheimer's infusions in the US, and per-report medico-legal fees from law firms. Go-to-market is hybrid: enterprise business development targeted at pharma/biotech sponsors (including through the PPD Select Partnership Programme with Thermo Fisher Scientific and Global Alzheimer's Platform Foundation membership), direct-to-consumer self-pay with NHS and private medical professional referrals, and sales-led outreach to personal injury solicitors. The company was founded in 2011, expanded to the US in 2018, and is led by co-founder and CEO Dr. Emer MacSweeney. It was the first organization globally to achieve GCSA clinical site certification from IAOCR in both the US and Europe, and is one of the largest providers of amyloid-targeting therapies in Europe.

Re:Cognition Health firmographics

Firmographics
Name
Re:Cognition Health
Legal name
Re:Cognition Health Limited
Website
https://recognitionhealth.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
Re:Cognition Health operates 10 cognitive healthcare clinics across the UK and US, delivering Phase II/III clinical trials for global pharmaceutical sponsors, private-pay cognitive assessments and disease-modifying Alzheimer's treatments (Leqembi, Kisunla), and medico-legal expert witness services in neurology and brain injury.
Ownership category
akta.pro rank

Re:Cognition Health industry classification

Industry
Product category
Neurology and Cognitive Healthcare Services
NAICS
Offices of Physicians, Mental Health Specialists (621112), Offices of Mental Health Practitioners (except Physicians) (621330), Services for the Elderly and Persons with Disabilities (62412)
SIC
Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAKAIAH
Cognitive & Behavioral Neurology (Dementia/Memory Disorders)
SECONDARYHLADALAF
Dementia/Alzheimer’s Care Management & Behavioral Support
Healthcare & Life Sciences/Elder Care & Long-Term Care/Senior Care Coordination & Case Management (Geriatric Care Management)
SECONDARYHLADACAE
Behavioral Health–Integrated Dementia Care Communities (Neuropsychiatric/BPSD Programs)
Healthcare & Life Sciences/Elder Care & Long-Term Care/Memory Care (Dementia/Alzheimer’s) Communities
SECONDARYHSABAEAC
Alzheimer’s Specialized Care (Mid/Late-Stage)
Home & Personal Services/Elder Care & In-Home Care Services/Dementia & Alzheimer’s In-Home Care

Keywords

  • Cognitive healthcare services
  • Clinical trial site network
  • Alzheimer's disease treatment
  • Medico-legal expert witness
  • Neurological assessment services

Where Re:Cognition Health is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices10 records

Markets served

Re:Cognition Health business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Clinical Trial Services for Pharma & Biotech Sponsors: Re:Cognition Health earns fees from pharmaceutical and biotech companies (Eli Lilly, AbbVie, ANAVEX, CervoMed, MSD, Sage Therapeutics, Biohaven, Amneal, AC Immune) for conducting Phase II–III clinical trials at their UK and US sites. Revenue is earned per patient enrolled, screened, and randomized, with study durations ranging from 6 weeks to 3 years. The company negotiates centralized contracts and budgets for multi-site UK/US trials.
  2. Private Pay Healthcare Services: Revenue from self-pay patients accessing private cognitive health assessments (CognitionCheck), Alzheimer's disease-modifying treatments (Leqembi, Kisunla), ADHD and autism assessments, mental health services, neurology clinics, and therapeutic apheresis. Services are available to UK and international patients at the company's six UK clinic locations. Medicare coverage is accepted for FDA-approved Alzheimer's treatments at US clinics.
  3. Medico-Legal Expert Witness Services: Revenue from law firms and barrister chambers for expert witness reports, medical assessments, 3T MRI scans, and court testimony in personal injury and clinical negligence cases involving brain injury, neurological conditions, and cognitive impairment. The company works with leading personal injury law firms on high-value catastrophic injury cases.
  4. Medicare Reimbursement (US Clinics): US clinics receive Medicare reimbursement for FDA-approved amyloid-targeting Alzheimer's medications (Leqembi and Kisunla) for early-stage Alzheimer's patients, providing a recurring revenue stream from the federal health insurance program at the company's four US clinic locations.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goClinical trial participation — free to volunteers with expenses reimbursed
SubscriptionPay-as-you-goPrivate cognitive health services — fee-based, quote on inquiry
OtherPay-as-you-goMedico-legal expert witness services — fee-based per report/assessment

Go-to-market motion3 records

Distribution channels8 records

Marketing channels10 records

Re:Cognition Health product offering

Product offering

Core offering

Re:Cognition Health operates a network of private cognitive healthcare clinics delivering AI-integrated diagnosis, disease-modifying Alzheimer's treatments (Leqembi and Kisunla), Phase II–III clinical trial site services for pharmaceutical and biotech sponsors, and medico-legal expert witness reports for personal injury and clinical negligence law firms. Its CognitionCheck assessment combines AI cognitive testing, MRI imaging, p-Tau217 blood biomarker analysis, and specialist physician consultation in a single pathway for adults aged 50 and over.

Product overview

Re:Cognition Health is a healthcare company offering a comprehensive portfolio of cognitive healthcare services centered around brain and mind health. The core offerings include CognitionCheck (AI-powered comprehensive cognitive assessment), Alzheimer's treatments (Leqembi and Kisunla), clinical trials for multiple neurological conditions, and private clinics. Additional services span ADHD and autism assessments, mental health services, neurology clinics, medico-legal expert witness services, and advanced imaging technologies including DTI. The company operates across multiple UK locations and four U.S. clinics, combining clinical care with research to advance treatments for Alzheimer's disease and other cognitive conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • CognitionCheck A comprehensive cognitive health assessment for adults aged 50 and over combining AI-powered cognitive testing, MRI brain imaging, p-Tau217 blood biomarker analysis, and specialist physician consultation within a single integrated clinical pathway to detect early signs of Alzheimer's disease and cognitive decline.
  • Alzheimer's Disease-Modifying Treatments (Leqembi and Kisunla) Private administration of monoclonal antibody therapies (Leqembi/lecanemab and Kisunla/donanemab) that target and clear amyloid-beta plaques in the brain to slow cognitive decline in early-stage Alzheimer's disease, with Medicare coverage for FDA-approved medications at US clinics.
  • Clinical Trials (Phase II–III Site Services) Phase II–III clinical trial site services for pharmaceutical and biotech sponsors across Alzheimer's, Mild Cognitive Impairment, Parkinson's, ADHD, Migraine, Autism, and Multiple Sclerosis, including rapid study start-up, centralized UK/US contracting, and budget negotiation.
  • Medico-Legal Expert Witness Services Expert witness reports and medical assessments in neurology, neuropsychiatry, neuroradiology, and neuropsychology for personal injury and clinical negligence cases involving brain injury, supported by 3T MRI and DTI imaging, with capacity assessments and court testimony.
  • Private Cognitive Healthcare Clinics

Quantifiable outcome

  • Kisunla (donanemab) slowed cognitive decline by 35% in total study population over 18 months, up to 60% in MCI participants, and reduced loss of daily function by 40%. One-third of patients achieved amyloid clearance by 6 months.
  • +5 more outcomes

Companies that use Re:Cognition Health

Customer profile

Named customers11 records

Segments5 records

Ideal customer profiles3 records

Re:Cognition Health technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Re:Cognition Health partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and supporting.

  • CeracoreStrategic or Co-development Partner · 20 February 2026Re:Cognition Health and Cera partnered in February 2026 to improve access to Alzheimer's Disease and neurodegenerative clinical trials by linking home care with specialist research centres. The collaboration aims to facilitate early referral, assessment, and trial participation for patients who are currently difficult to reach through traditional clinic-based methods. Home healthcare visits enable screening and monitoring that would otherwise require clinic visits, expanding the reach of clinical trials to housebound or mobility-limited patients.
  • Re:Cognition Health Brain and Mind FoundationsupportingOthers · 1 December 2025The Brain and Mind Foundation was launched by Re:Cognition Health in December 2025 to drive meaningful change, fund hope, and improve lives for those affected by neurological conditions. The Foundation harnesses the company's trans-Atlantic clinical expertise to fund breakthrough research, advance earlier diagnosis, and champion adoption of new biomarkers. It operates as a fundraising and research funding vehicle engaging donors, partners, and the wider community.
  • Scan.comsupportingTechnology or Integration · 1 June 2025Re:Cognition Health partnered with Scan.com to provide MRI imaging access to patients nationwide through a network of more than 300 imaging centres across the UK. This partnership makes CognitionCheck assessments geographically accessible to patients regardless of their proximity to company clinic locations, extending the reach of the company's diagnostic services across the entire UK.
  • Thermo Fisher Scientific (PPD Clinical Research)coreStrategic or Co-development Partner · 1 August 2024Re:Cognition Health UK and US site networks are preferred sites within the PPD Select Partnership Programme of Thermo Fisher Scientific's PPD clinical research business, a global leader in clinical research. The relationship provides preferential access to clinical trial opportunities and strategic site collaborations across the company's 10 existing sites. This is described as an exciting relationship bringing significant opportunities for the company's clinical trial operations.
  • Global Alzheimer's Platform (GAP) FoundationcoreStrategic or Co-development Partner · 1 June 2018Re:Cognition Health is the only non-US/Canadian member of the Global Alzheimer's Platform Foundation, a patient-centric nonprofit dedicated to speeding the delivery of innovative Alzheimer's therapies by reducing the time and cost of clinical trials. This membership provides access to a global network of research sites and pharma partnerships, and positions the company as a preferred global partner for Alzheimer's clinical research.
  • Inova Memory Center, Inova Fairfax HospitalcoreStrategic or Co-development Partner · 1 June 2018The first US clinic (Fairfax, Virginia) operates in partnership with Inova Memory Center at Inova Fairfax Hospital. Dr. James Bicksel, Neurologist and Medical Director of Inova Memory Center, serves as Principal Investigator at the US site. The Inova Memory Center is a leading memory programme in the Washington D.C. area, adding clinical credibility and referral pathways to the company's US operations.

Scale indicators8 records

Recent moves9 records

Expansion highlights7 records

Re:Cognition Health competitors and assessment

Company assessment

Direct peers

  • Cambridge Cognition: UK-based provider of digital cognitive assessment technologies used in clinical trials and healthcare. Highly comparable because both companies deliver cognitive testing to pharma trial sponsors and run proprietary assessment platforms (CognitionCheck vs CANTAB).
  • MAC Clinical Research: UK-based clinical trial site network operating dedicated early and late-phase research clinics. Directly comparable to Re:Cognition Health's UK trial operations — both are private UK site networks running multi-therapeutic Phase II–III studies for global pharma sponsors.
  • Cogstate: Australia/US-based provider of computerized cognitive testing for clinical trials, healthcare, and academic research. Comparable to Re:Cognition Health as both monetize cognitive assessment in pharma-sponsored trials and neurodegenerative drug development.
  • Richmond Pharmacology: UK clinical research organization specializing in early-phase clinical trials, including CNS studies. Comparable because it operates UK-based clinical trial infrastructure serving global pharma — similar customer base and regulatory complexity to Re:Cognition Health's trial services.
  • Compass Pathways: UK-headquartered mental health clinical-stage company running psychedelic therapy clinical trials for treatment-resistant depression. Comparable because both operate UK-based specialist clinical research operations for CNS indications targeting a similar regulatory and patient-recruitment environment.

Emerging players

  • Alto Neuroscience: Clinical-stage neuroscience company using biomarkers to develop precision psychiatry therapeutics and running trials in depression and ADHD. Comparable emerging overlap with Re:Cognition Health's adult ADHD assessment and psychiatry services for CNS drug development.

Others

  • Cerveau Technologies: Provider of tau PET imaging ligands used in Alzheimer's disease clinical research. Comparable as an adjacent enabling partner in the same Alzheimer's biomarker ecosystem that Re:Cognition Health's CognitionCheck and clinical trial business operates within.

Broad incumbents

  • Clario: Global clinical trial technology and imaging company (formed via merger of Bioclinica and ERT) supporting CNS trials with imaging, eCOA, and biomarker solutions. Comparable as a broad incumbent serving the same pharma sponsors on neurodegenerative trials that Re:Cognition Health runs as a site.
  • IXICO: UK-listed neuroimaging analytics company providing imaging biomarkers and AI tools for neurodegenerative clinical trials. Comparable to Re:Cognition Health's DTI/3T MRI and CognitionCheck imaging components, but operates as a technology vendor rather than a clinic operator.

Regional players

  • Inova Memory Center: US-based memory disorders clinical and research program operated within Inova Fairfax Hospital. Comparable to Re:Cognition Health's Fairfax US site as both deliver specialist Alzheimer's and memory-disorder diagnosis, treatment, and clinical trial participation in the Washington DC metropolitan area.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Re:Cognition Health social profiles

Digital presence

Re:Cognition Health compliance and trust

Trust signal

Compliance9 records

Re:Cognition Health financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Re:Cognition Health leadership team

Management profile

Number of profiles

Profiles14 records

Re:Cognition Health funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Re:Cognition Health M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Re:Cognition Health

What does Re:Cognition Health do?

Re:Cognition Health operates a network of private cognitive healthcare clinics delivering AI-integrated diagnosis, disease-modifying Alzheimer's treatments (Leqembi and Kisunla), Phase II–III clinical trial site services for pharmaceutical and biotech sponsors, and medico-legal expert witness reports for personal injury and clinical negligence law firms. Its CognitionCheck assessment combines AI cognitive testing, MRI imaging, p-Tau217 blood biomarker analysis, and specialist physician consultation in a single pathway for adults aged 50 and over.

Is Re:Cognition Health a public or private company?

Re:Cognition Health is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Re:Cognition Health founded?

Re:Cognition Health was founded in 2018. It employs 101 to 250 people.

Where is Re:Cognition Health based?

Re:Cognition Health is headquartered in London, United Kingdom, in the Europe region.

How does Re:Cognition Health make money?

Four revenue lines are on record. Clinical Trial Services for Pharma & Biotech Sponsors are the primary driver. The others are private Pay Healthcare Services, medico-Legal Expert Witness Services and medicare Reimbursement (US Clinics).

Who are Re:Cognition Health's main competitors?

Direct peers on record are Cambridge Cognition, MAC Clinical Research, Cogstate, Richmond Pharmacology and Compass Pathways. Alto Neuroscience is listed as an emerging player. Cerveau Technologies is listed as an others. Broad incumbents are Clario and IXICO. Inova Memory Center is listed as a regional player.

Does Re:Cognition Health have an API?

No public API is recorded for Re:Cognition Health.

What industry is Re:Cognition Health in?

Re:Cognition Health's product category is Neurology and Cognitive Healthcare Services. Its primary akta.pro industry code is HLAKAIAH, Cognitive & Behavioral Neurology (Dementia/Memory Disorders), with a secondary code of HLADALAF, Dementia/Alzheimer’s Care Management & Behavioral Support. Its NAICS code is 621112 and its SIC code is 8011.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Healthcare TodayNew assessment for earlier detection of Alzheimer’sLondon-based Re:Cognition Health has launched CognitionCheck, a new service combining AI cognitive testing, blood biomarker analysis, and MRI imaging to detect Alzheimer's disease earlier in adults over 50. The service is delivered in partnership with Scan.com, which provides the MRI scans at over 300 centres across the UK. Priced at £1,295, the assessment aims to facilitate earlier diagnosis and treatment for neurodegenerative conditions.Longevity.TechnologyNew Alzheimer therapies trigger diagnostic shakeupRe:Cognition Health launched CognitionCheck, a £1,295 multi-modal screening pathway combining MRI, AI testing, and p-Tau217 blood biomarkers. A Nature Communications study validated remote capillary blood sampling for Alzheimer's biomarkers, enabling decentralized testing. The convergence signals a shift toward low-cost, ambient monitoring for population-scale screening.PR NewswireRe:Cognition Health Achieves Global Clinical Site Assessment Recertification at its U.S. ClinicsRe:Cognition Health has successfully renewed its Global Clinical Site Assessment (GCSA) Site Certification from the International Accrediting Organization for Clinical Research (IAOCR) at its four U.S. clinics. The company was the first organization to achieve GCSA certification in both the U.S. and Europe when it initially received the designation in 2024, and currently hosts 60 clinical trials across its U.S. sites. The certification reflects IAOCR's assessment of the company's operational excellence, team culture, and patient-centered focus across seven critical business areas.BioSpaceRe:Cognition Health Achieves Global Clinical Site Assessment Recertification at its U.S. ClinicsRe:Cognition Health renewed its Global Clinical Site Assessment certification at four U.S. clinics, becoming the first organization to achieve this in both the U.S. and Europe. The certification covers 60 clinical trials for Alzheimer's and related conditions. The company cited its team's professionalism and patient-centered focus.PR NewswireRe:Cognition Health Delivers Landmark International Clinical Trial to Explore Whether a Simple Finger-prick Blood-based Biomarker Test Can Provide Earlier Alzheimer's DiagnosisRe:Cognition Health has launched an international clinical trial to evaluate whether a simple finger-prick blood test can diagnose Alzheimer's disease earlier, more affordably, and more accessibly than current invasive and costly methods such as brain imaging and lumbar punctures. The trial will enroll approximately 1,000 participants across the United Kingdom, United States, and Canada, comparing blood-based biomarker results against traditional diagnostic methods including amyloid PET scans, MRI imaging, and cognitive assessments. The study is led by the Global Alzheimer's Platform Foundation with funding from LifeArc and support from the UK Dementia Research Institute, and could enable earlier intervention using amyloid-targeting therapies such as Kisunla and Leqembi.PR NewswireInc. Names Re:Cognition Health Co-Founder and CEO Dr. Emer MacSweeney to Its 2026 Female Founders 500 ListRe:Cognition Health Co-Founder and CEO Dr. Emer MacSweeney has been named to Inc.'s 2026 Female Founders 500, an annual list honoring influential women business leaders in the United States. Under her leadership, Re:Cognition Health has become a global leader in Alzheimer's treatments, having helped develop and trial amyloid-targeting therapies including Lilly's Kinsula and Eisai's Leqembi, which are now available to patients. Dr. MacSweeney was the first clinician in Europe to administer Kinsula outside a clinical trial and recently administered Bahrain's first-ever dose of the treatment.MorningstarInc. Names Re:Cognition Health Co-Founder and CEO Dr. Emer MacSweeney to Its 2026 Female Founders 500 ListRe:Cognition Health co-founder and CEO Dr. Emer MacSweeney has been named to Inc.'s 2026 Female Founders 500 list, an annual honor recognizing dynamic women business leaders in the United States. Under her leadership, Re:Cognition Health has played a key role in translating amyloid-targeting therapies including Eli Lilly's Kinsula and Eisai's Leqembi from clinical trials into accessible patient treatments, becoming one of the largest providers of ATT medications in Europe. Dr. MacSweeney was the first clinician in Europe to administer Kinsula outside a clinical trial setting and recently oversaw administration of Bahrain's first-ever dose of the treatment.Digital HealthPartnership aims to expand access to Alzheimer’s clinical trialsRe:Cognition Health and Cera have partnered to improve access to Alzheimer's Disease and neurodegenerative clinical trials by linking home care with specialist research centers. The collaboration aims to facilitate early referral, assessment, and trial participation for patients, especially those who are currently difficult to reach through traditional clinic-based methods.PR NewswireRe:Cognition Health Announces Medicare Coverage for FDA-Approved Early-Stage Alzheimer's Disease Treatments at Its Four U.S. ClinicsRe:Cognition Health announced that Medicare now covers FDA-approved amyloid-targeting medications Leqembi™ and Kisunla™ at its U.S. clinics in Fairfax, Chicago, Houston, and Fort Worth. The treatment, aimed at early-stage Alzheimer's disease patients, helps slow cognitive decline by reducing amyloid-beta plaques in the brain. The company emphasizes the importance of early detection and immediate access to treatment to maximize patient outcomes.